Compare JVA & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JVA | PMCB |
|---|---|---|
| Founded | 1971 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2M | 6.3M |
| IPO Year | 1997 | 2001 |
| Metric | JVA | PMCB |
|---|---|---|
| Price | $3.94 | $0.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 69.1K | ★ 321.9K |
| Earning Date | 06-12-2026 | 03-17-2026 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $90,655,294.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.76 | ★ N/A |
| Revenue Growth | ★ 17.54 | N/A |
| 52 Week Low | $2.93 | $0.33 |
| 52 Week High | $5.03 | $1.51 |
| Indicator | JVA | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 55.38 | 41.32 |
| Support Level | $3.30 | $0.33 |
| Resistance Level | $4.07 | $0.77 |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 63.01 | 58.23 |
Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.